Omeros Corporation
OMER
$9.97
$0.121.22%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
5/14/2026
-
MarketBeat
6/9/2026
-
Tickeron - Stocks
6/4/2026
-
Zacks Investment Research
6/2/2026
-
Seeking Alpha - Healthcare
6/2/2026
-
SeekingAlpha
6/1/2026
-
Fool.com Headlines
5/29/2026
-
Tickeron - Stocks
5/27/2026
-
The Cerbat Gem
5/27/2026
-
TipRanks Financial Blog
5/21/2026
-
Tickeron - Stocks
5/19/2026
-
Tickeron - Stocks
5/18/2026
-
ETF Channel
5/16/2026
-
Tickeron - Stocks
5/15/2026
-
Simply Wall St
5/15/2026
-
The Cerbat Gem
5/15/2026
-
TipRanks Financial Blog
5/14/2026
-
Simply Wall St
5/14/2026
-
Fool.com Headlines
5/14/2026
-
TipRanks Financial Blog
5/14/2026
-
TipRanks Financial Blog
5/14/2026
-
Tickeron - Stocks
5/14/2026
-
TipRanks Financial Blog
5/14/2026
-
SeekingAlpha.com: All News
5/14/2026
-
Seeking Alpha - Healthcare
10/23/2025
-
MarketBeat
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, May 13, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
206 676 5000
Address
The Omeros Building
Seattle, WA 98119
Seattle, WA 98119
Country
Year Founded
Business Description
Sector
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic...
more